Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Fish

Orthopaedic Surgery of the Spine Smyrna, TN Doctor of Osteopathy

NPI 1821046459 CMS profile 127649

300 Stonecrest Blvd Ste 230, Smyrna, TN 37167

Open in the dashboard

General payments

$6,146

109 records reported · program years 2019–2025

Research payments

$3,000

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$782,400

4 holdings reported · through program year 2025

Through program year 2025, James Fish of Smyrna, TN is reported in the CMS Open Payments database as having received $6,146 across 109 general payments and $3,000 in research payments paid to them. They also declared ownership or investment interests valued at $782,400 across 4 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,109 28
2024 General $1,385 24
2024 Research $3,000 10
2023 General $1,249 18
2022 General $1,105 9
2021 General $689 7
2020 General $237 6
2019 General $371 17
2022 Ownership $238,000 1
2021 Ownership $184,400 1
2020 Ownership $180,000 1
2019 Ownership $180,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Fish
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to James Fish were reported at $1,109. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year James Fish Orthopaedic Surgery of the Spine median Middle half National median
2019 $371 $2,106 $337–$18,608 $163
2020 $237 $1,213 $156–$15,082 $114
2021 $689 $1,834 $271–$15,617 $132
2022 $1,105 $2,015 $320–$17,036 $149
2023 $1,249 $1,925 $336–$14,599 $160
2024 $1,385 $2,110 $341–$12,483 $164
2025 $1,109 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimvie Inc. $1,429 6 payments
  2. Zimmer Biomet Holdings, Inc. $912 5 payments
  3. Intrinsic Therapeutics $896 16 payments
  4. Providence Medical Technology, Inc. $442 11 payments
  5. Ebi, LLC $277 1 payment
  6. Highridge Medical LLC $261 1 payment
  7. SI-BONE, Inc. $249 7 payments
  8. Elevation Spine, Inc. $217 2 payments
  9. Abbott Laboratories $200 9 payments
  10. Amgen Inc. $199 10 payments
  11. Other $1,064 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,146 109 payments
Products named General payments · program years 2019–2025
  1. Biomet SpinalPak Non-invasive Spine Fusion Stimulator System Bone Healing $1,467 6 payments
  2. BARRICAID ACD (ANNULAR CLOSURE DEVICE) Annular Closure Device $843 15 payments
  3. BARRICAID ACD (ANNULAR CLOSURE DEVICE) Annular Closure Device $843 15 payments
  4. Biomet SpinalPak $555 2 payments
  5. Biomet SpinalPak / OrthoPak $325 1 payment
  6. BIOMET SPINALPAK NON-INVASIVE SPINE FUSION STIMULATOR SYSTEM Not Applicable $277 1 payment
  7. Mobi-C $224 1 payment
  8. IFUSE IMPLANT $211 5 payments
  9. EVENITY $199 10 payments
  10. OsteoCentric 4.0 x 130mm LOCKING BONE SCREW FASTENER ST $141 2 payments
  11. Other $1,430 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Intrinsic Therapeutics $3,000 10 payments

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,552

Median for Orthopedic Surgery: 203

Drug cost

$18,056

Median for Orthopedic Surgery: $1,433

Branded share of claims

24%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 291 $4,124
Lidocaine Generic 36 $3,097
Gabapentin Generic 246 $2,479
Diclofenac Sodium Generic 100 $1,592
Methylprednisolone Generic 151 $1,218
Celecoxib Generic 26 $1,194
Meloxicam Generic 261 $903
Pregabalin Generic 80 $849
Tizanidine Hcl Generic 59 $781
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 81 $510

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$129,280

Of which drugs: $118

Medicare patients

156

Average age 72

Services billed

2,054

98 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 35%
Diabetes 30%
Ischemic heart disease 28%
Chronic kidney disease 28%
Osteoporosis 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 11 1,248 $100

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Tymlos
  • Radius Health, Inc. $18
$18 — —
EVENITY
  • Amgen Inc. $15
$15 — —
Prolia
  • Amgen Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record